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Abstract
Expression of the CC chemokine receptor 1 (CCR1) by tumor cells has been associated with protumoral activity;
however, its role in nontumoral cells during tumor development remains elusive. Here, we investigated the role of
CCR1 deletion on stromal and hematopoietic cells in a liver metastasis tumor model. Metastasis development was
strongly impaired in CCR1-deficient mice compared to control mice and was associated with reduced liver mono-
cyte infiltration. To decipher the role of myeloid cells, sublethally irradiated mice were reconstituted with CCR1-
deficient bone marrow (BM) and showed better survival rates than the control reconstituted mice. These results
point toward the involvement of CCR1myeloid cell infiltration in the promotion of tumor burden. In addition, survival
rates were extended in CCR1-deficient mice receiving either control or CCR1-deficient BM, indicating that host
CCR1 expression on nonhematopoietic cells also supports tumor growth. Finally, we found defective tumor-
induced neoangiogenesis (in vitro and in vivo) in CCR1-deficient mice. Overall, our results indicate that CCR1
expression by both hematopoietic and nonhematopoietic cells favors tumor aggressiveness. We propose CCR1
as a potential therapeutical target for liver metastasis therapy.
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Introduction
Chemokines are small chemoattractant cytokines that bind to seven-
transmembrane domain G protein–coupled receptors. A large number
of chemokines are secreted by most, if not all, tumor cells. They are
implicated in a wide spectrum of tumor environment–related processes,
including tumor spreading [1], tumor survival [2], and angiogenesis
[3]; however, the major effect of chemokines is proposed to be on
immune cell recruitment [4].
It is now well described that the infiltration of tumors by leuko-
cytes, and more specifically macrophages, could have a protumoral
activity [5]. The tumoral environment progressively reprograms infil-
trating macrophages, also termed tumor-associated macrophages
(TAMs), resulting in a progressive loss of antitumor activity. This
is shown by reduced potency of antigen presentation [6], cell cyto-
toxicity, Th1 cytokine secretion and enhanced tumor survival, and
production of proangiogenic, tissue modeling, and anergistic cyto-
kines [7]. High infiltration of tumors by macrophage-like cells in
humans and mice is associated with poor survival [5] and high angio-
genesis [8] and has been described to favor metastasis formation and
dissemination [9].
The CC chemokine receptor 1 (CCR1) is primarily expressed
by cells of myeloid lineage, including monocytes, neutrophils, and
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dendritic cells but also by some T lymphocytes and intimal smooth
muscle–like cells. In a mouse colorectal tumor model, tumor cell
invasion, metastasis formation, and myeloid progenitor cell recruit-
ment were inhibited in CCR1−/− mice or after administration of
CCR1 pharmacological blockade [10,11], suggesting that CCR1-
dependent myeloid infiltration has a protumoral effect. In addition,
it has been proposed that CCR1 promotes tumor spreading and
angiogenesis by controlling metalloproteinase secretion [12]. In this
study, we used a model of liver tumor metastasis development and
provided, for the first time, evidence of CCR1 expression by non-
tumoral cells favoring hepatocellular metastasis development through
control of both mononuclear cell infiltration and angiogenesis.
Materials and Methods
Mice
Female C57Bl/6 mice (Charles River, Lyon, France) were main-
tained under specific pathogen-free conditions on a 12-hour light-dark
cycle. CCR1-deficient mice (CCR1−/−) on C57Bl/6 background were
provided by Drs Philippe Murphy and Ji Liang Gao (Laboratory of
Molecular Immunology, National Institute of Allergy and Infectious
Diseases, National Institutes of Health, Bethesda, MD). CCR1−/−
mice were back-crossed eight generations with C57Bl/6 green fluores-
cent protein [(GFP); C57Bl/6-Tg(UBC-GFP)30Scha/J] mice from
The Jackson Laboratory (Bar Harbor, ME) to obtain CCR1−/− GFP
mice. GFP expression were detected in all tissues examined and used to
track leukocytes after transplantation. Mice used for experiments were
8 to 10 weeks old. Animal experiments were approved by the local In-
stitutional Animal Care and Use Committee of Centre d’Exploration
Fonctionelle, Pitié-Salpétrière.
Cell Lines
The C57BL/6 dimethylbenzanthracene-induced thymoma EL-4
was maintained in RPMI 1640 (Invitrogen Life Technologies,
Paisley, Scotland) supplemented with 10% heat-inactivated fetal
calf serum (FCS; Seromed, Berlin, Germany), 2 mM L-glutamine,
1000 U/ml penicillin, 1 mg/ml streptomycin, 250 ng/ml amphotericin
B (Invitrogen Life Technologies), and 3 μM 22-ME (Sigma-Aldrich,
St Louis, MO).
Tumor Models
C57BL/6 control mice or CCR1−/− mice were injected in the tail
vein with 5 × 105 EL-4. In another model, mice received subcutaneous
(s.c.) injections of 1 × 105 tumor cells in 100 μl of phosphate-buffered
saline (PBS) in the right flank. Tumor size was measured three times a
week with calipers, and tumor volume was estimated using the follow-
ing formula: width × length × (width + length)/2. Mice were sacrificed
when the tumor volume reached approximately 3 cm3.
Flow Cytometry
At day 12 after EL-4 tail vein injection, harvested livers were cut into
small pieces and digested with 400 units of collagenase D (Roche
Diagnostics GmbH, Mannheim, Germany) for 30 minutes. Cell sus-
pensions were filtered through a 70-μm cell strainer (BD Biosciences,
Bedford, MA) and isolated with density separation medium (Histopaque
1083; Sigma-Aldrich). Leukocytes were collected, washed in PBS, and
labeled for flow cytometry using the following monoclonal antibodies:
antibody to CD11b (anti–CD11b PerCP-Cy5), anti–Ly-6G PE, anti–
Ly-6C-biotin, anti–CD4 PE, anti–CD3 Alexa Fluor 488, anti–CD8a
Alexa Fluor 647, NK1.1 Alexa Fluor 647, anti–CD11c APC, and
streptavidin-PerCP (all sourced from BD Pharmingen, San Diego, CA).
Anti-mouse neutrophil 7/4 Alexa Fluor 488 and Alexa Fluor 647 were
from AB Serotec (Oxford, United Kingdom). Cell suspensions were
incubated with appropriate fluorochrome-conjugated monoclonal
antibodies and analyzed on a FACSCalibur cytofluorimeter (Becton
Dickinson, Franklin Lakes, NJ). Results were analyzed with CellQuest
Pro software (Becton Dickinson).
Bone Marrow Chimeras
Control and CCR1−/− recipient mice were irradiated with 10-Gy
radiation using an ORION linear accelerator (General Electric
Healthcare, Milwaukee, WI). Whole bone marrow (BM) from either
control GFP mice [C57BL/6-Tg(UBC-GFP)30Scha/J] or transgenic
CCR1−/− GFP (see Mice section) was extracted from the tibia and
femur. Donor cells (5 × 106) were injected into recipient mice through
the retro-orbital vein. Twelve weeks after transplant, recipient mice
were injected with EL-4 thymoma cells.
Aortic Rings
Control and CCR1−/−mice aortas were isolated and cut into small
segments. These were placed in Matrigel (BD Biosciences)–coated
42-well plates containing 10% FCS in Dulbecco’s modified Eagle’s
medium (DMEM) culture medium. Cultures were incubated at 37°C
and 5% CO2 for 6 days, and explants were monitored for sprouting
vessels. For the EL-4–conditioned medium experiments, cultured
media were removed from wells after 3 days and replaced by 50%
DMEM, 10% FCS + 50% RPMI, 10% FCS or 50% DMEM, 10%
FCS + 50% EL-4–conditioned RPMI, 10% FCS. After fixation and
4′,6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich) staining, ves-
sel formation was quantified by measuring the area of vessel-like exten-
sions from the explants using ImageJ 1.39U software.
CD31 and Lectin Immunohistochemical Staining
At day 12 after EL-4 tail vein injection, 6-μm frozen liver sections
from control and CCR1−/− mice were fixed with 4% paraformal-
dehyde for 10 minutes, washed three times for 5 minutes in PBS,
and incubated overnight at 4°C with anti-CD31 (AB Serotec) or anti-
lectin (Sigma-Aldrich) antibody. CD31 staining was visualized with
r-phycoerythrin (RPE)-conjugated anti-rabbit Ig antibody (Invitrogen,
Carlsbad, CA). Lectin- and CD31-positive areas in tumoral and non-
tumoral livers were visualized by scanning sections at low magnifica-
tion (×20). The number of microvessels was recorded in six randomly
chosen fields of view using ImageJ 1.39U software.
Reverse Transcription–Polymerase Chain Reaction
Total RNA was extracted from sorted hepatic endothelial cells (ECs),
peripheral blood mononuclear cells (PBMCs), or cultured EL-4 using
Qiagen Micro Kit (Qiagen, Hilden, Germany), according to the man-
ufacturer’s instructions. Total RNA was reverse transcribed to cDNA
using SupertScript Reverse Transcriptase (Invitrogen). Real-time poly-
merase chain reaction was carried out using SYBR Premix (Invitrogen)
with the primer sets described inTableW1. To standardizemRNA con-
centrations, transcript levels of glyceraldehyde 3-phosphate dehydrogenase
(GAPDH ) were determined in parallel for each sample, and relative
transcript levels were corrected by normalization on the basis of GAPDH
transcript levels.
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Statistical Analysis
Mann-Whitney test and/or log-rank (Mantel-Cox) test were used
to determine whether variation in experimental groups was signifi-
cant using GraphPad Prism software (GraphPad, San Diego, CA).
Results
CCR1 Deficiency Increases Survival in Tumor Metastasis
Engraftment Models
After IV injection of control C57BL/6 mice into the tail vein, EL-4
thymoma cells selectively grew in the liver and kidney. The mortality
occurred approximately 3 weeks after tumor cell injection, and after
32 days, all of the mice had died (Figure 1A). Interestingly, in this
tumor model, the CCR1-deficient mice (CCR1−/−) survived longer
than control mice, with a mean survival of 27.5 and 23 days, respec-
tively (Figure 1A). In addition, 20 days after IV tumor cell injection,
livers from CCR1−/−mice were much smaller in size than those from
control mice, 2.1 ± 0.2 and 3.4 ± 0.4 g, respectively (Figure 1B). To
confirm the role of CCR1 in tumor growth, we set up a second model
in which tumor cells were injected s.c. While all control mice devel-
oped palpable tumors 6 days after s.c. injection, only half of the
CCR1−/− mice showed the presence of tumors at day 8 (Figure 1C ).
After 3 weeks, 30% of the CCR1−/− mice remained tumor-free, as
opposed to all of the control mice that had developed tumors. The
mean volume of EL-4 tumors in CCR1−/−mice was less than in con-
trol mice at all time points (Figure 1D). These results indicate that
host cell CCR1 expression favors tumor aggressiveness.
CCR1 Deficiency Is Associated with Decreased Infiltration of
Myeloid Cells into Tumors
To better understand how CCR1 activation may promote liver
metastasis development, we analyzed the leukocyte infiltration during
early stages of tumor development. Analyses were performed 12 days
after IV tumor injection in the liver and the kidney. At this stage,
tumor foci are undetectable macroscopically. Using flow cytometry,
we identified tumor cell infiltrates as myeloid infiltrates based on
CD11bhi and NK 1.1neg expression (gate 1 in Figure 2A, left panel ).
Inflammatory monocytes were discriminated from the so-called
“patrolling” monocytes based on 7/4 expression level [13] (gates 2
and 3 in Figure 2A, right panel). There was a strict co-expression
between 7/4 marker and Ly6C, the marker commonly used to dis-
criminate monocyte subpopulations as previously published [13] (in
Supplementary data). Inflammatory monocytes were defined as 7/4hi,
Ly6Chi, Ly6Gneg cells and resident monocytes as 7/4lo, Ly6Cint/lo,
Ly6Gneg cells. Neutrophils were defined as 7/4hi Ly6Chi Ly6Ghi
cells (gate 4). CD4 and CD8 lymphocytes were defined as, respectively,
CD3+ CD4+ NK1.1− and CD3+ CD8+ cells, whereas NK cells were
defined as CD3− NK1.1+ cells and NKT as CD3+ NK1.1+ cells (not
Figure 1. Lack of CCR1 reduces tumor development. (A) Survival curve of C57BL/6 control mice (solid line) or C57BL/6 CCR1−/− mice
(dotted line) injected IV with 5 × 105 EL-4. Mean survival time of CCR1−/−mice (n = 28) was 20% longer than in control mice (n = 19).
(B) Twenty-one days after tumor inoculation, the increase in liver weight is smaller in CCR1−/− mice compared to WT mice. Each data
point represents the mean tumoral liver weight ± SEM of 10 mice. (C) CCR1−/− mice (dotted line, n = 11) showed delay tumor ap-
parition compared to control mice (solid line, n = 11), log-rank test, P= .005. (D) Tumor size growth in control mice (solid line, n = 11) or
CCR1−/−mice (dotted line, n= 11) injected s.c. with 1 × 105 EL-4. Tumor development is delayed in CCR1−/−mice. *P< .05; **P< .01
(mice with tumor size of >3 cm3 were killed).
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shown). Interestingly, a major effect on leukocyte recruitment in the
CD11b + myeloid compartment was observed (Figure 2B, left panel),
with a 50% reduction in CCR1−/−mouse liver (6.6% and 3% of total
cells, respectively, P < .001). This was associated with reduced infiltra-
tion of both inflammatory (3.5% and 1.5%, P = .005) and “patrolling”
monocytes (1% and 0.5%, P = .014). We did not observe any signif-
icant differences in the neutrophil infiltrate. In the lymphocyte com-
partment (Figure 2B, middle panel ), only CD3+ CD8+ cells were
present in larger number in the livers of CCR1−/− mice compared to
those of control mice (Figure 3B; P = .043), whereas CD3+ CD4+,
NK, andNKT cells were unaltered (Figure 3B,middle and right panels).
Analysis of the kidney infiltrates showed similar trends with reduced
monocyte and CD8+ cell infiltration (Figure W1). The concomitant
decrease of TAM infiltration, with the increase of cytotoxic CD8T cells,
may indicate a better control of tumor immunosuppression by the
immune system in CCR1−/− mice.
Figure 2. CCR1 deficiency alters leukocyte recruitment at the tumor site. (A) Dot plot analysis identified tumoral leukocyte subpopulation
infiltrates by flow cytometry analysis: 1, myeloid cells; 2, inflammatory monocytes; 3, resident monocytes; 4, neutrophils. (B) CCR1−/−
mice show defect in the myeloid cell mobilization, mainly due to a defect recruitment of the 7/4 + monocyte population. Percentages
± SEM were indicated for each group (control in black, n = 10; CCR1−/− in white, n = 10) and were obtained from two independent
experiments. Np, neutrophils; significant value of *P < .05, **P < .001, and ***P < .001.
Figure 3. CCR1 expression by both BM and non–BM-derived cells promotes tumor metastasis. Survival curve of CCR1−/− and control
chimeric mice injected IV with 5 × 105 EL-4. Chimeric mice resulted from control and CCR1−/− irradiated hosts reconstituted with
CCR1−/− GFP or control GFP BM. CCR1−/− hosts with control BM (open squares; n = 7) and WT host with control BM (filled squares;
n = 9) had significantly decreased mean survival than mice of the same genotype with CCR1 BM, respectively, WT host with CCR1 BM
(open circles; n = 10) and CCR1 host with CCR1 BM (filled circles; n = 11 mice).
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Protumoral Effect of CCR1 Is Due to Expression on
Both Hematopoietic and Nonhematopoietic Cells
We hypothesized that in addition to CCR1-driven protumoral leu-
kocyte recruitment, nonhematopoetic cells expressing CCR1may also
favor tumor growth, as proposed previously for CCR5 [14]. To delin-
eate the contribution of CCR1 on hematopoietic cells compared to
nonhematopoietic cells, we performed BM chimera experiments.
We first assessed the effect of CCR1 deletion on leukocyte subpopu-
lation engraftment. The distributions of lymphocytes, NK, monocytes,
and neutrophils in the blood of wild type (WT) mice irradiated and
reconstituted with WT or CCR1−/− BM or in the blood of CCR1−/−
mice irradiated and reconstituted with WT BM were unchanged, in-
dicating that the lack of CCR1 expression by either hematopoietic or
nonhematopoietic cells did not altered engraftment (Figure W2).
CCR1−/− and control mice were sublethally irradiated and recon-
stituted with BM cells from either GFP control or CCR1−/− GFP
transgenic mice (Figure 3). All mice showed greater than 90% of
GFP-positive leukocytes (data not shown). After EL-4 IV injection,
both control (open squares) and CCR1−/− recipient (open circles) mice
showed increased survival when reconstituted with CCR1−/− BM
compared to their respective controls, with median survival of 14 and
20 days (P < .001) and 15 and 23 days (P = .01), respectively. This
indicates that hematopoietic cell CCR1 expression favors EL-4 burden.
Surprisingly, survival rates were extended in CCR1−/− mice receiving
either control (filled circles) or CCR1−/− (open circle) BM,withmedian
survival of 20 and 23days (P = .018). This suggests that the expression of
CCR1 by nonhematopoetic cells also contributes to tumor growth.
Lack of CCR1 Led to Reduce Hepatic Capillary Density during
Early-Stage Tumor Development
We postulated that CCR1 may also control metastasis development
by regulating tumor-induced vascularization. To test this hypothesis,
we measured the blood capillary density in the control or CCR1−/−
mouse livers at a time point where tumors were not macroscopically
detectable (Figure 4A, left and right panels, respectively). Twelve days
after tumor inoculation, the liver microvessel density as assessed by
CD31 staining was increased by more than three-fold (P = .004) in
control mice, whereas it was only modestly increased in CCR1−/−mice
(Figure 4B). Similar results were obtained with lectin staining
(Figure W3). These results indicated that tumor development is
associated with enhanced hepatic capillary density before we could
detect the tumoral foci and strongly suggested that CCR1 promoted
tumor-associated vascularization of the liver.
CCR1 Deficiency Led to Reduced Monocyte-
Independent Neoangiogenesis
Because CCR1 may favor tumor-associated vascularization, we
investigated the role of CCR1 in an in vitro angiogenesis model sup-
posedly independent of the circulating leukocytes. We compared the
vessel sprouting around aortic ring from control and CCR1−/− mice
(Figure 5A, left and right panels, respectively). After 6 days in culture,
the area of vessel-like extensions from CCR1−/− explants was about
50% smaller than those of control explants (Figure 5B). These data
suggest that CCR1 promotes EC outgrowth, independent of recruited
myeloid cell with proangiogenic properties. To further investigate the
mechanism associated with EL-4–induced angiogenesis in the liver, we
compared the vessel sprouting around aortic ring from control and
CCR1−/− mice in the presence of EL-4–conditioned media. EL-4
supernatant increased vessel sprouting from WT mouse aortic ring
compared to control media by 55% (P = .0085). In these conditions,
vessel sprouting of CCR1−/− aortic ring was strongly inhibited (57%,
P < .001), indicating that EL-4 promoted CCR1-dependent angio-
genesis in a hematopoietic-independent model. To support the
hypothesis that similar mechanisms may take place in the tumor micro-
environment, we investigated the expression of CCR1 in sorted hepatic
ECs (Figure 5C ) and of its ligands in the EL-4 tumoral cell line
(Figure 5D). CCR1 transcripts were strongly expressed in PBMCs
and were also detected in hepatic ECs. EL-4 expressed high level of
CCL5 but no CCL3, indicating that EL-4 secretion may directly
Figure 4. Reduced numbers of microvessels in tumoral liver of CCR1−/−mice. (A) Frozen liver sections from CCR1−/− and control mice
injected with tumor cells were stained with anti-CD31 antibody. Control staining was performed by only incubating with the secondary
antibody. (B) Number of microvessels were counted in six randomly chosen fields. Each value represents mean ± SEM (n= 6). *P< .05,
**P < .001 compared to D0, #P < .05 compared to control mice.
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activate hepatic ECs. Altogether, these data support the model of
CCR1-triggered angiogenesis in the absence of hematopoietic cells.
Discussion
While lymphocyte infiltration is usually associated with good prog-
nosis [15], tumor-associated myeloid lineage cells are almost always
associated with poor survival, increased tumor spreading, and metas-
tases [5]. The roles of several chemokines in controlling human tumor
development or spreading have been well demonstrated [16]. Several
polymorphisms in human chemokine genes affect patient prognosis
markers, possibly by controlling TAM recruitment [17,18]. The pro-
tumoral effect of CCR1 by tumor cells has been described in several
mouse tumor models [19–22]. This study focused on the role of
CCR1, expressed by stromal cells but not tumor cells. Our data indi-
cate that tumor development is impaired in CCR1−/− mice, in both
the tumor metastasis implantation model and tumor growth model,
compared to control mice. We showed that CCR1 expression on both
hematopoietic and nonhematopoietic cells impaired mouse survival.
The better survival of the CCR1−/− mice is associated with both the
reduction in infiltration of myeloid lineage cells and highest level of
infiltration of CD8 T cells. Moreover, angiogenesis is defective in
CCR1−/− mice both in vivo and in vitro.
It was previously proposed that CCR1 controls immature myeloid
cell recruitment in tumors, therefore promoting tumor development
[10,11]. Here, we show that CCR1 is also involved in the recruit-
ment of mature myeloid cells, mainly altering monocyte but not neu-
trophil infiltration. Although neutrophils express CCR1, the kinetics of
their recruitment may differ from that of monocytes. Alternatively,
neutrophils may be recruited by other tumor-secreted chemokines,
such as Cxcl8, which could compensate for the lack of CCR1.
CCR1 deficiency affects slightly more inflammatory monocyte infiltra-
tion than “patrolling” monocyte infiltration. Some chemokine recep-
tors, like Ccr2 or Cx3cr1, are known to be differentially expressed by
these subsets of monocytes, but there are no clear evidences concerning
CCR1 [23]. However, a previous report indicated that the CCR1 RNA
expression level is two to three times higher in 7/4hi monocytes than
7/4lo from the blood [24]. Nonetheless, the implication of CCR1 in
migratory properties of different subsets of monocytes should be
completed to confirm that CCR1 is preferentially implicated in 7/4hi
monocyte migration than 7/4lo monocyte migration. We also observed
enhanced CD8 T lymphocyte infiltration in CCR1−/− mice, likely to
result from the tumor microenvironment alteration in CCR1−/−mice.
Globally, both reduction in the protumoral myeloid compartment
and enhanced cytotoxic CD8 T cell infiltration may play a role in
the improved control of tumor development in CCR1 mice. The role
of CCR1 expressed by nontumoral cells remains ambiguous in tumor
development. Although the expression of CCR1 by cells of myeloid
lineage may promote tumor development, several models support the
idea that CCR1 may favor antitumor immune response when tumor
immunotolerance is thwarted. For instance, the antitumoral effect of
radiofrequency ablation was enhanced by an agonist of CCR1 in a
murine hepatocellular carcinoma model. This effect was associated with
increased infiltration of the radiofrequency ablation–treated tumor by
lymphocytes and CCR1-positive dendritic cells. In CCR1−/− mice,
both the leukocyte recruitment and antitumor effect, induced by the
CCR1 agonist, were inhibited [25]. Taken together, the CCR1 axis
may control the subtle balance between innate protumoral activity
and adaptative antitumoral responses.
The tumor-induced vascular capillary density was reduced in
CCR1-deficient mice. These results confirm previous observation
made by Yang et al. in a model of induced hepatocellular carcinoma
[12], although our data indicated that this effect was dependent on
host CCR1 expression and not due to tumor cells that were CCR1
competent. The cellular origin of the neovasculature in this model is
not clearly established, as the ability of BM-derived cells to integrate
vessel has been proposed in an aggressive tumor model. However, we
demonstrated that EL-4 supernatant promotes angiogenesis ex vivo
independently of hematopoietic cells. Moreover, the vessel density
was measured before macroscopic tumor detection, suggesting that,
at that time, mostly hepatic vasculature was altered. Hence, even if
we cannot exclude it, the contribution of hematopoietic cells in the
formation of the neovessel wall is likely to be minor. Consistent with
previous studies performed with CCR5−/− mice [14], we demon-
strated, using BM transfer experiments, that tumor aggressiveness
is not only dependent on CCR1 expression by stromal hematopoietic
cells but also on its expression by stromal nonhematopoetic cells.
Indeed, stromal nonhematopoetic cells have already been associated
Figure 5. Lack of CCR1 reduces neoangiogenesis in a vessel
sprouting assay. (A) Representative photomicrography of aortic ring
with vessel sprouting. The outgrowth area was measured between
the vessel growth front and the base of the aortic ring. (B) Vessel
sprouting in control and CCR1-deficient aortic ring. Outgrowth area
was measured in the absence or presence of EL-4–conditioned
media. Each value represents mean area ± SEM (n = 12). (C) Level of
CCR1 transcripts in hepatic ECs and PBMCs from WT and CCR1−/−
mice. ECs were isolated by flow cytometry and defined as CD45−
F4/80− CD31+ cells. (D) Level of CCR1 ligand transcripts (CCL3
and CCL5) in EL-4. ***P < .001 compared to WT and ##P < .01
compared to control media.
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with tumor development, promoting angiogenesis [26] or metastasis
formation [27]. Surprisingly, when irradiated and reconstituted with
BM from control mice, CCR1-deficient mice have a longer survival
than irradiated control mice reconstituted with homologous control
BM. This indicates that CCR1 expression by nonhematopoetic cells
also contributes to tumor aggressiveness. The angiogenesis aortic ring
model, with or without condition media from EL-4 culture, con-
firmed that EL-4 secreted cytokines that promote angiogenesis in
the absence of hematopoietic cells by CCR1-dependent mechanism.
It is not clear which cell population, present in the aorta, controls
new capillary formation in a CCR1-dependent mechanism. How-
ever, we showed here that CCR1 mRNA was expressed by hepatic
EC. These results are in accordance with previous work showing the
expression of CCR1 mRNA by rat EC [28] and the ability of human
EC lines to migrate and differentiate when stimulated with a CCR1
agonist [29]. Moreover, the high expression of CCL5 transcript, but
not CCL3, by EL-4 was consistent with the direct proangiogenic
effect of CCL5 through binding on CCR1 expressed by EC [30].
In addition, the mesenchymal stem cells present in the media of
the aorta express CCR1 transcript [31], and recent insights support
the role of CCR1 expression by mesenchymal stem cells in angio-
genesis [32]. We show that the protumoral effect of CCR1 was medi-
ated by both hematopoietic and nonhematopoietic CCR1-expressing
cells. However, the relative importance of each compartment remains
unclear. The percentage of recruitment of only some leukocyte popu-
lations is affected in CCR1 null mice, suggesting that these defects of
recruitment did not result from reduced angiogenesis. In addition, the
concomitant defect in infiltration of the tumor by monocytes and
strong diminution of the capillary density in CCR1−/− is consistent
with our recent finding that inflammatory monocytes promote post-
ischemic neovascularization [33]. Interestingly, we did not observe
any differences when we compared the hepatic artery network by
microangiography in control and CCR1−/− mice, 12 days after EL-4
injection (data not shown). These data suggest that the role of CCR1
on angiogenesis is restricted to capillary vessels, and not larger arteries,
at least during early-stage metastasis development.
In conclusion, we showed that both hematopoietic and stromal
cells participate in CCR1-dependent protumoral activity. CCR1 defi-
ciency limited tumor progression and increased mouse survival rates.
These beneficial effects were associated with reduced monocyte mobi-
lization and reduced tumoral neovascularization. Further experiments
should be performed to confirm the pertinence of using CCR1 as a
therapeutic target in the control of metastasis development.
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Table W1. RT-PCR Primer Sequences.
Genes Forward Reverse
CCL5 GCTGCCCTCACCATCATCCTCACT GGCACACACTTGGCGGTTCCTTC
CCL3 GTGCCCTTGCTGTTGTTGTGTGAT CTGCCGGTTTCTCTTCGTCAGGA
CCR1 TTAGCTTCCATGCCTGCCTTATA TCCACCTGCTTCAGGCTCTTGT
GAPDH CCTGGAGAAACCTGCCAAGTATG AGAGTGGGAGTTGCTGTTGACTC
Figure W1. CCR1 deficiency alters leukocyte recruitment at the tumor site. (A) CCR1−/− mice showed defects in the myeloid and
lymphoid cell mobilization in the kidney at day 12 post-tumor inoculation. Percentages (± SEM) were indicated for each group (control
in black, n = 5; CCR1−/− in white, n = 5). Np, neutrophils; significant value of *P < .05 and **P < .001.
Figure W2. CCR1 expression by hematopoietic or nonhematopoietic cells do not alter the peripheral leukocyte distribution after BM
transfer. Percentages of circulating total monocytes, inflammatory monocytes, resident monocytes, neutrophils, NK, and lymphocytes
were evaluated 8 weeks after irradiation of WT or CCR1−/− recipients reconstituted with WT or CCR1−/− BM; n = 3 to 5 mice.
Figure W3. Reduced numbers of microvessels in tumoral liver of
CCR1−/− mice. Frozen liver sections from CCR1−/− and control
mice injected with tumor cells were stained with lectin antibody.
The number of microvessels was counted in six randomly chosen
fields. Each value represents mean ± SEM (n = 6 to 8). **P < .01
compared to D0; ##P < .01 compared to control mice.
